GlassScriptPhysician profile
Michelle M Zhang
NPI 1366553513
$2,251.53
in general payments reported to CMS, 2019-2025
19 companies · $818 in 2025
The $818 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2021: $136 · 2022: $159 · 2023: $371 · 2024: $330 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,498 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,497.62 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $834.68 | 2019-2025 | Verzenio |
| Glaxosmithkline, LLC. | $266.81 | 2019-2025 | Trelegy Ellipta |
| Abbvie INC. | $202.60 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $179.41 | 2019-2024 | Enhertu |
| Genentech, INC. | $132.13 | 2025 | Itovebi |
| Janssen Pharmaceuticals, INC | $106.45 | 2019 | |
| Stemline Therapeutics INC. | $93.48 | 2025 | Orserdu |
| Pfizer INC. | $80.34 | 2024-2025 | |
| Janssen Biotech, INC. | $78.71 | 2025 | Tecvayli, Darzalex, Erleada |
| Foundation Medicine, INC. | $49.31 | 2023 | |
| Celgene Corporation | $42.63 | 2025 | Reblozyl |
| Regeneron Healthcare Solutions, INC. | $34.41 | 2022 | |
| Hologic Sales and Service, LLC | $30.81 | 2025 | Novasure, Myosure Tissue Removal Device, Fluent Fluid Management System |
| E.R. Squibb & Sons, L.L.C. | $25.50 | 2019 | |
| Tempus Ai, INC | $23.04 | 2025 | Xt Cdx |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Seagen INC. | $20.91 | 2019 | |
| Morphosys, US INC. | $17.39 | 2023 | Monjuvi |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.